Invesco
CGEM icon

Invesco’s Cullinan Oncology CGEM Stock Holding History

Invesco’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Sell
143,552
-100,598
-41% -$1.49M ﹤0.01% 2463
2026
Q1 		$3.47M Buy
244,150
+113,827
+87% +$1.46M ﹤0.01% 2324
2025
Q4 		$1.35M Buy
130,323
+28,011
+27% +$253K ﹤0.01% 2780
2025
Q3 		$607K Buy
102,312
+41,757
+69% +$306K ﹤0.01% 3157
2025
Q2 		$456K Buy
60,555
+11,312
+23% +$90.9K ﹤0.01% 3196
2025
Q1 		$373K Sell
49,243
-10,310
-17% -$98.9K ﹤0.01% 3276
2024
Q4 		$725K Buy
59,553
+1,395
+2% +$20.1K ﹤0.01% 3053
2024
Q3 		$974K Buy
58,158
+8,797
+18% +$156K ﹤0.01% 2916
2024
Q2 		$861K Buy
49,361
+1,954
+4% +$41.6K ﹤0.01% 3009
2024
Q1 		$808K Buy
47,407
+36,784
+346% +$568K ﹤0.01% 3092
2023
Q4 		$108K Buy
+10,623
New +$94.1K ﹤0.01% 3676
2023
Q1 		– Sell
-10,057
Closed -$106K – 3883
2022
Q4 		$106K Sell
10,057
-76
-0.8% -$923 ﹤0.01% 3812
2022
Q3 		$129K Buy
10,133
+19
+0.2% +$256 ﹤0.01% 3788
2022
Q2 		$129K Sell
10,114
-1,720
-15% -$19.5K ﹤0.01% 3839
2022
Q1 		$124K Buy
11,834
+203
+2% +$2.74K ﹤0.01% 3848
2021
Q4 		$180K Buy
11,631
+2,504
+27% +$49.9K ﹤0.01% 3807
2021
Q3 		$205K Buy
+9,127
New +$244K ﹤0.01% 3793

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Invesco's CGEM Position: Q2 2026 in Review

Invesco reduced its Cullinan Oncology (CGEM) stake by 41% in Q2 2026, selling an estimated $1.49M and leaving 143,552 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2463.

Invesco first reported a position in CGEM in Q3 2021 and has held it in 17 quarters since. The position peaked at $3.47M in Q1 2026. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Invesco held 143,552 shares of Cullinan Oncology worth $2.61M as of Q2 2026.
  • Invesco sold 100,598 Cullinan Oncology shares in Q2 2026, an estimated $1.49M.
  • Cullinan Oncology made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2463 holding.
  • Invesco first reported a position in Cullinan Oncology in Q3 2021 and has held it in 17 quarters since.
  • Invesco's Cullinan Oncology position peaked at $3.47M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.